Pfizer cuts profit forecast on patent loss (Crain’s New York Business)

Pfizer cuts profit forecast on patent loss (Crain’s New York Business)
The drugmaker trimmed its outlook to account for the loss of patent protection for its second best-selling drug, Norvasc.